pharmaceutical investing ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart maintains high levels of viral suppression in long-acting HIV treatment regimen
pharmaceutical investing U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
pharmaceutical investing Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans
pharmaceutical investing Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
pharmaceutical investing PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
pharmaceutical investing Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
pharmaceutical investing Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
CHARBONE confirme la livraison de nouvelles commandes d'hydrogene UHP dans l'Etat de New York, un des principaux poles technologiques americains
